Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ST316 by Sapience Therapeutics for Metastatic Breast Cancer: Likelihood of Approval
ST316 is under clinical development by Sapience Therapeutics and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
Lucicebtide by Sapience Therapeutics for Sarcomas: Likelihood of Approval
Lucicebtide is under clinical development by Sapience Therapeutics and currently in Phase II for Sarcomas. According to GlobalData, Phase II...
Lucicebtide by Sapience Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Lucicebtide is under clinical development by Sapience Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...
Lucicebtide by Sapience Therapeutics for Gastrointestinal Tract Cancer: Likelihood of Approval
Lucicebtide is under clinical development by Sapience Therapeutics and currently in Phase II for Gastrointestinal Tract Cancer. According to GlobalData,...
Lucicebtide by Sapience Therapeutics for Signet Ring Cell Squamous Cell Carcinoma: Likelihood of Approval
Lucicebtide is under clinical development by Sapience Therapeutics and currently in Phase II for Signet Ring Cell Squamous Cell Carcinoma....